Status:
COMPLETED
Schizophrenia, Antipsychotic Treatment and the Risk for Diabetes Mellitus
Lead Sponsor:
University of Pittsburgh
Collaborating Sponsors:
American Association for Geriatric Psychiatry
Janssen Pharmaceuticals
Conditions:
Schizophrenia
Schizoaffective Disorder
Eligibility:
All Genders
14-50 years
Brief Summary
This preliminary study aims to investigate the mechanism of higher rates of type 2 diabetes mellitus in patients with schizophrenia. As part of the study, we collect neuroendocrine-immune data on pati...
Detailed Description
This preliminary study aims to investigate the mechanism of higher rates of type 2 diabetes mellitus in patients with schizophrenia. As part of the study, we collect neuroendocrine-immune data on pati...
Eligibility Criteria
Inclusion
- Psychotic disorder as per DSM-IV criteria of the American Psychiatric Association
Exclusion
- Diabetes, type 1 or 2
- Prominent substance abuse (i.e. psychotic symptoms attributable entirely to substance use)
- Age above 50 or age below 14
Key Trial Info
Start Date :
August 1 2003
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 1 2016
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT00222807
Start Date
August 1 2003
End Date
March 1 2016
Last Update
August 28 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Pittsburgh
Pittsburgh, Pennsylvania, United States, 15213